MCID: STV007
MIFTS: 41

Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Categories: Rare diseases

Aliases & Classifications for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

MalaCards integrated aliases for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:

Name: Stevens-Johnson Syndrome/toxic Epidermal Necrolysis 20 43
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum 20 43
Drug-Induced Stevens Johnson Syndrome 20 43
Toxic Epidermal Necrolysis 20 43
Stevens-Johnson Syndrome 20 43
Susceptibility to Severe Cutaneous Adverse Reaction Ity to 20
Mycoplasma-Induced Stevens Johnson Syndrome 43
Lyell's Syndrome 43
Sjs/ten 20

Classifications:



Summaries for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

GARD : 20 Stevens-Johnson syndrome /toxic epidermal necrolysis (SJS/TEN) is a very severe reaction, most commonly triggered by medications, that causes skin tissue to die (necrosis) and detach. The mucous membranes of the eyes, mouth, and/or genitals are also commonly affected. SJS and TEN previously were thought to be separate conditions, but they are now considered part of a disease spectrum. SJS is at the less severe end of the spectrum, and TEN is at the more severe end. It is considered SJS when skin detachment involves less than 10% of the body surface, and TEN when skin detachment involves more than 30% of the body surface. People with skin detachment involving 10-30% of the body surface are said to have "SJS/TEN overlap." All forms of SJS/TEN are a medical emergency that can be life-threatening. The first symptoms of SJS/TEN often include fever and flu-like symptoms (such as general ill feeling, body aches, and cough). Within about 1 to 3 days, a red or purplish rash forms, and then the skin begins to blister and peel, leading to "raw" areas of skin that are painful. This often starts on the face and then spreads to other parts of the body. The mucous membranes may also become involved during this time, which can lead to symptoms such as severe conjunctivitis (when the eyes are affected), trouble swallowing and breathing (when the mouth and airway are affected), and difficulty urinating and genital pain (when the genitals are affected). SJS/TEN often is triggered by certain medications including allopurinol, anti-epileptics, pain relievers, cancer therapies, or antibiotics (sometimes up to 2 weeks after stopping the medication). SJS/TEN can also be triggered by infections such as pneumonia, herpes virus, and hepatitis A. In many cases the cause cannot be identified. People that may be at increased risk to develop SJS/TEN include those with HIV, a weakened immune system, a personal or family history of the condition, and certain variations of a gene called HLA-B. There are no universal diagnostic criteria for SJS/TEN. Currently the diagnosis is based on the person's medical history and symptoms. People suspected of having SJS/TEN should be admitted to the hospital to confirm the diagnosis and assess severity. As mentioned earlier, whether a person is diagnosed specifically with SJS, TEN, or SJS/TEN overlap depends on the percentage of body surface area affected. Treatment needs should be assessed in the hospital to determine severity and where treatment should be provided (e.g. intensive care unit, burn unit, or dermatology unit). Treatment may involve stopping a triggering medication (for those suspected of having medication-induced SJS/TEN), standard therapies used for major burns, various eye treatments (for those with eye involvement), pain control, and preventing and treating infections. The overall mortality rate is about 25%, ranging from about 10% for SJS to over 30% for TEN. The most common causes of death include sepsis, acute respiratory distress syndrome, and multiple organ failure. Those that survive may experience recurrence (particularly if re-exposed to a trigger) and/or long-term complications involving the skin and affected mucous membranes.

MalaCards based summary : Stevens-Johnson Syndrome/toxic Epidermal Necrolysis, also known as stevens-johnson syndrome toxic epidermal necrolysis spectrum, is related to severe cutaneous adverse reaction and conjunctivitis. An important gene associated with Stevens-Johnson Syndrome/toxic Epidermal Necrolysis is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

MedlinePlus Genetics : 43 Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe skin reaction most often triggered by particular medications. Although Stevens-Johnson syndrome and toxic epidermal necrolysis were once thought to be separate conditions, they are now considered part of a continuum. Stevens-Johnson syndrome represents the less severe end of the disease spectrum, and toxic epidermal necrolysis represents the more severe end.SJS/TEN often begins with a fever and flu-like symptoms. Within a few days, the skin begins to blister and peel, forming very painful raw areas called erosions that resemble a severe hot-water burn. The skin erosions usually start on the face and chest before spreading to other parts of the body. In most affected individuals, the condition also damages the mucous membranes, including the lining of the mouth and the airways, which can cause trouble with swallowing and breathing. The painful blistering can also affect the urinary tract and genitals. SJS/TEN often affects the eyes as well, causing irritation and redness of the conjunctiva, which are the mucous membranes that protect the white part of the eye and line the eyelids, and damage to the clear front covering of the eye (the cornea).Severe damage to the skin and mucous membranes makes SJS/TEN a life-threatening disease. Because the skin normally acts as a protective barrier, extensive skin damage can lead to a dangerous loss of fluids and allow infections to develop. Serious complications can include pneumonia, overwhelming bacterial infections (sepsis), shock, multiple organ failure, and death. About 10 percent of people with Stevens-Johnson syndrome die from the disease, while the condition is fatal in up to 50 percent of those with toxic epidermal necrolysis.Among people who survive, long-term effects of SJS/TEN can include changes in skin coloring (pigmentation), dryness of the skin and mucous membranes (xerosis), excess sweating (hyperhidrosis), hair loss (alopecia), and abnormal growth or loss of the fingernails and toenails. Other long-term problems can include impaired taste, difficulty urinating, and genital abnormalities. A small percentage of affected individuals develop chronic dryness or inflammation of the eyes, which can lead to increased sensitivity to light (photophobia) and vision impairment.

Related Diseases for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Diseases related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 613)
# Related Disease Score Top Affiliating Genes
1 severe cutaneous adverse reaction 31.9 IKZF1 HLA-C HLA-B HLA-A
2 conjunctivitis 31.0 IL13 HLA-B
3 paraneoplastic pemphigus 30.4 HLA-C HLA-B HLA-A
4 skin disease 30.4 IL13 HLA-C HLA-B
5 human cytomegalovirus infection 30.4 HLA-C HLA-A
6 aphthous stomatitis 30.3 HLA-B HLA-A
7 severe acute respiratory syndrome 30.3 HLA-C HLA-A
8 autoimmune disease 30.2 IL13 HLA-B HLA-A
9 immune deficiency disease 30.2 IL13 HLA-B HLA-A
10 uveitis 30.2 HLA-B HLA-A
11 penicillin allergy 30.1 IL13 HLA-B
12 graft-versus-host disease 30.1 HLA-C HLA-B HLA-A
13 tetanus 30.1 IL13 HLA-A
14 rubella 30.0 HLA-C HLA-B HLA-A
15 pars planitis 30.0 HLA-B HLA-A
16 pure red-cell aplasia 30.0 HLA-B HLA-A
17 herpes zoster 29.9 HLA-B HLA-A
18 porphyria cutanea tarda 29.9 HLA-B HLA-A
19 psoriasis 29.8 IL13 HLA-C HLA-B HLA-A
20 leprosy 3 29.6 IL13 HLA-B HLA-A
21 viral infectious disease 29.6 IL13 HLA-B HLA-A
22 human immunodeficiency virus type 1 29.6 HLA-C HLA-B HLA-A
23 sarcoidosis 1 29.5 IL13 HLA-A
24 psoriatic arthritis 29.5 IL13 HLA-C HLA-B HLA-A
25 alopecia areata 29.2 IL13 HLA-C HLA-B HLA-A
26 stevens-johnson syndrome/toxic epidermal necrolysis overlap syndrome 11.8
27 erythema multiforme 11.5
28 erythema multiforme major 11.5
29 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 11.5
30 ritter's disease 11.4
31 5-oxoprolinase deficiency 11.2
32 auditory neuropathy spectrum disorder 11.2
33 exanthem 10.8
34 allergic disease 10.8
35 hypereosinophilic syndrome 10.7
36 drug reaction with eosinophilia and systemic symptoms 10.7
37 pemphigus 10.6
38 pemphigoid 10.6
39 bullous pemphigoid 10.6
40 acute graft versus host disease 10.6
41 yemenite deaf-blind hypopigmentation syndrome 10.6
42 acute generalized exanthematous pustulosis 10.6
43 purpura 10.5
44 acquired immunodeficiency syndrome 10.5
45 granulocytopenia 10.5
46 dowling-degos disease 1 10.5
47 neutropenia 10.5
48 gout 10.5
49 bronchiolitis 10.5
50 acute kidney failure 10.5

Graphical network of the top 20 diseases related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:



Diseases related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Symptoms & Phenotypes for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

GenomeRNAi Phenotypes related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 10.9 HLA-A HLA-B HLA-C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 10.9 HLA-A HLA-B HLA-C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 10.9 HLA-C
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 10.9 HLA-A HLA-B HLA-C
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 10.9 HLA-A HLA-B HLA-C
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 10.9 HLA-A HLA-B HLA-C
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 10.9 HLA-C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 10.9 HLA-A HLA-B HLA-C
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.9 HLA-A HLA-B HLA-C
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.9 HLA-C
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.9 HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.66 HLA-A HLA-B HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.66 HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.66 HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.66 HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.66 HLA-C
17 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.66 HLA-A HLA-B HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.66 HLA-C

Drugs & Therapeutics for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Drugs for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Molgramostim Investigational Phase 4 99283-10-0
4 Cyclosporins Phase 4
5 Immunosuppressive Agents Phase 4
6 Calcineurin Inhibitors Phase 4
7 Anti-Infective Agents Phase 4
8 Antifungal Agents Phase 4
9 Ophthalmic Solutions Phase 4
10
Coal tar Approved Phase 3 8007-45-2
11
Etanercept Approved, Investigational Phase 3 185243-69-0
12
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
13
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
14 Immunologic Factors Phase 2, Phase 3
15 Anti-Inflammatory Agents Phase 3
16 Analgesics, Non-Narcotic Phase 3
17 Analgesics Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 3
19 Pharmaceutical Solutions Phase 2, Phase 3
20 Adjuvants, Immunologic Phase 2, Phase 3
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
22
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 1, Phase 2 83-88-5 493570
23 Vitamin B9 Phase 1, Phase 2
24 Nutrients Phase 1, Phase 2
25 Micronutrients Phase 1, Phase 2
26 Trace Elements Phase 1, Phase 2
27 Photosensitizing Agents Phase 1, Phase 2
28 Vitamins Phase 1, Phase 2
29 Vitamin B Complex Phase 1, Phase 2
30 Vitamin B2 Phase 1, Phase 2
31 Folate Phase 1, Phase 2
32
tannic acid Approved Phase 1 1401-55-4
33
Benzocaine Approved, Investigational Phase 1 1994-09-7, 94-09-7 2337
34 Anesthetics Phase 1
35 Anesthetics, Local Phase 1
36
Isotretinoin Approved 4759-48-2 5282379 5538
37
Allopurinol Approved 315-30-0 2094
38 Anti-Bacterial Agents
39 Immunoglobulin A
40 Immunoglobulins
41 gamma-Globulins
42 Antibodies
43 Immunoglobulins, Intravenous
44 Rho(D) Immune Globulin

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
3 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
4 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
5 NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 Harmonized supportive care;Cyclosporine 5 mg/kg bid days 0-14;Etanercept 50 mg sc day 0 and day 3
6 Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes) Not yet recruiting NCT04651439 Phase 2, Phase 3 Filgrastim;Placebo
7 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
8 Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial Not yet recruiting NCT04711200 Phase 1, Phase 2 Adipose derived stromal cells intravenously injected
9 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
10 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
11 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
12 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
13 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
14 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Completed NCT03878771 Phase 1 Dermovate cream in Orabase
15 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Unknown status NCT02795143 Isotretinoin
16 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
17 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
18 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Unknown status NCT02574988
19 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
20 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
21 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
22 Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients Recruiting NCT04252651
23 An Evaluation of Tangible Boost Replenishing System for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Versus Host Disease Recruiting NCT04313725
24 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
25 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
26 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732
27 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT03585946 Site specific standard of care comparison

Search NIH Clinical Center for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Genetic Tests for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Anatomical Context for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

MalaCards organs/tissues related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:

40
Skin, Eye, T Cells, Salivary Gland, Bone Marrow, Thymus, Endothelial

Publications for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Articles related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:

(show top 50) (show all 3584)
# Title Authors PMID Year
1
U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. 61 20
27317286 2016
2
Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
33055536 2021
3
SkinSerious: Disseminated intravascular coagulation complicating Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
33515629 2021
4
A beginner's guide to mucous membrane grafting for lid margin keratinization: Review of indications, surgical technique and clinical outcomes. 61
33727438 2021
5
Mortality and risk factors on admission in toxic epidermal necrolysis: A cohort study of 59 patients. 61
33279401 2021
6
Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus. 61
33657677 2021
7
Cohort study of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in China: evaluation of risk models and new predictor of pulmonary consolidation on computed tomography. 61
33644844 2021
8
Patients', family members' and healthcare practitioners' experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis: a qualitative descriptive study using emotional touchpoints. 61
32977354 2021
9
Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation. 61
32561372 2021
10
Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients. 61
33474859 2021
11
Involvement of small-diameter nerve fibres in long-term chronic pain after Stevens-Johnson syndrome or toxic epidermal necrolysis. A neurophysiological assessment. 61
32920914 2021
12
Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis in a large retrospective cohort. 61
32289398 2021
13
Diphtheroids as Corneal Pathogens in Chronic Ocular Surface Disease in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
33758140 2021
14
Direct Injection of 5-Fluorouracil Improves Outcomes in Cicatrizing Conjunctival Disorders Secondary to Systemic Disease. 61
32427724 2021
15
Detecting Lesional Granulysin Levels for Rapid Diagnosis of Cytotoxic T lymphocyte-Mediated Bullous Skin Disorders. 61
33039642 2021
16
Ciprofloxacin-induced cutaneous adverse drug events: a systematic review of descriptive studies. 61
33725760 2021
17
[Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis]. 61
33725172 2021
18
Levamisole induced toxic epidermal necrolysis: A case report. 61
32851655 2021
19
Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). 61
33650659 2021
20
Amniotic membrane transplantation in a 2-month-old infant with toxic epidermal necrolysis. 61
33521381 2021
21
MEEI special issue Fellows' PaperStevens Johnson syndrome: A review of a vision and life-threatening mucocutaneous disease including histopathology with updates on pathogenesis and genetic risk factors. 61
33764253 2021
22
Toxic Epidermal Necrolysis Like Lupus - A Case Series. 61
33760256 2021
23
Blistering severe cutaneous adverse reactions in children: Proposal for pediatric-focused clinical criteria. 61
33730370 2021
24
Characteristics of adverse drug reactions associated with antiepileptics at a tertiary children's hospital in Japan: A retrospective observational cohort study. 61
33740697 2021
25
In Silico Approach to Predict Severe Cutaneous Adverse Reactions Using the Japanese Adverse Drug Event Report Database. 61
33417306 2021
26
Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). 61
32846030 2021
27
Toxic epidermal necrolysis after therapeutic plasma exchange in pediatric lupus patients and associated risk factors analysis. 61
33413003 2021
28
Austrian syndrome followed by severe cutaneous adverse reactions in a HIV patient. 61
33071038 2021
29
Fatal toxic epidermal necrolysis probably related to glimepiride in a patient with a medical history of hypersensitivity to sulfamethoxazole-trimethoprim. 61
32815205 2021
30
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. 61
33795193 2021
31
Autologous scalp skin grafting to treat toxic epidermal necrolysis in a patient with a large skin injury: A case report. 61
33728308 2021
32
Changes in connexin 43 in inflammatory skin disorders: Eczema, psoriasis, and Steven-Johnson syndrome/toxic epidermal necrolysis. 61
33659713 2021
33
Bronchiolitis obliterans following toxic epidermal necrolysis: a case report. 61
33781322 2021
34
Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARS-CoV-2 viral RNA. 61
33439527 2021
35
The challenges of termination of pregnancy in the context of previous of Toxic Epidermal Necrolysis. 61
33745728 2021
36
Massive clonal expansion of polycytotoxic skin and blood CD8+ T cells in patients with toxic epidermal necrolysis. 61
33741590 2021
37
Toxic epidermal necrolysis induced by doxycycline. 61
33650113 2021
38
Investigating the association of Lamotrigine and Phenytoin-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with HLA-B*1502 in Iranian population. 61
33217035 2021
39
The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. 61
33635229 2021
40
A Systematic Review of Efficacy and Safety of Monotherapy and Combination Therapy With Biologic for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
33631950 2021
41
Acute and chronic ophthalmic involvement, severity & sequelae in Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. 61
33596622 2021
42
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with anticonvulsants in a Japanese population: Matched case-control and cohort studies. 61
33618992 2021
43
Mapping of susceptible variants for cold medicine-related Stevens-Johnson syndrome by whole-genome resequencing. 61
33574277 2021
44
Effect of older age on complications and mortality in inpatients with Stevens-Johnson syndrome or toxic epidermal necrolysis. 61
33621606 2021
45
Disseminated intravascular coagulopathy: a complication of Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
33332598 2021
46
Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention. 61
33639435 2021
47
Human leukocyte antigen B*0702 is protective against ocular Stevens-Johnson syndrome/toxic epidermal necrolysis in the UK population. 61
33536518 2021
48
Complete Fusion of Both Eyelids in Stevens-Johnson Syndrome: Case Report. 61
33528572 2021
49
Modeling the Bioactivation and Subsequent Reactivity of Drugs. 61
33496184 2021
50
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. 61
32779747 2021

Variations for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Expression for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Search GEO for disease gene expression data for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis.

Pathways for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Pathways related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.95 IL13 HLA-C HLA-B HLA-A
2
Show member pathways
12.6 HLA-C HLA-B HLA-A
3
Show member pathways
12.58 HLA-C HLA-B HLA-A
4
Show member pathways
12.56 HLA-C HLA-B HLA-A
5
Show member pathways
12.44 HLA-C HLA-B HLA-A
6 12.42 HLA-C HLA-B HLA-A
7
Show member pathways
12.2 IL13 HLA-C HLA-B HLA-A
8
Show member pathways
12.19 HLA-C HLA-B HLA-A
9
Show member pathways
12.16 HLA-C HLA-B HLA-A
10
Show member pathways
12.12 HLA-C HLA-B HLA-A
11 12.05 HLA-C HLA-B HLA-A
12 11.97 HLA-C HLA-B HLA-A
13 11.92 HLA-C HLA-B HLA-A
14 11.77 HLA-C HLA-B HLA-A
15 11.73 HLA-C HLA-B HLA-A
16 11.67 HLA-C HLA-B HLA-A
17 11.56 HLA-C HLA-B HLA-A
18 11.48 IL13 IKZF1
19
Show member pathways
11.47 IL13 HLA-C HLA-B HLA-A
20 10.2 HLA-C HLA-B HLA-A

GO Terms for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Cellular components related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.63 HLA-C HLA-B HLA-A
2 cell surface GO:0009986 9.58 HLA-C HLA-B HLA-A
3 early endosome membrane GO:0031901 9.54 HLA-C HLA-B HLA-A
4 recycling endosome membrane GO:0055038 9.5 HLA-C HLA-B HLA-A
5 secretory granule membrane GO:0030667 9.43 HLA-C HLA-B
6 phagocytic vesicle membrane GO:0030670 9.43 HLA-C HLA-B HLA-A
7 ER to Golgi transport vesicle membrane GO:0012507 9.33 HLA-C HLA-B HLA-A
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-C HLA-B HLA-A
9 MHC class I protein complex GO:0042612 8.8 HLA-C HLA-B HLA-A

Biological processes related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.76 IL13 HLA-C HLA-B HLA-A
2 immune system process GO:0002376 9.73 HLA-C HLA-B HLA-A
3 innate immune response GO:0045087 9.72 HLA-C HLA-B HLA-A
4 viral process GO:0016032 9.71 HLA-C HLA-B HLA-A
5 adaptive immune response GO:0002250 9.7 HLA-C HLA-B HLA-A
6 regulation of immune response GO:0050776 9.67 HLA-C HLA-B HLA-A
7 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.58 HLA-C HLA-B HLA-A
8 interferon-gamma-mediated signaling pathway GO:0060333 9.54 HLA-C HLA-B HLA-A
9 positive regulation of T cell mediated cytotoxicity GO:0001916 9.51 HLA-B HLA-A
10 type I interferon signaling pathway GO:0060337 9.5 HLA-C HLA-B HLA-A
11 detection of bacterium GO:0016045 9.48 HLA-B HLA-A
12 protection from natural killer cell mediated cytotoxicity GO:0042270 9.43 HLA-B HLA-A
13 antigen processing and presentation GO:0019882 9.43 HLA-C HLA-B HLA-A
14 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.33 HLA-C HLA-B HLA-A
15 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.13 HLA-C HLA-B HLA-A
16 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 8.8 HLA-C HLA-B HLA-A

Molecular functions related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.13 HLA-C HLA-B HLA-A
2 TAP binding GO:0046977 8.8 HLA-C HLA-B HLA-A

Sources for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....